Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | UNG | P13051 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591062 | 1.00 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL663469 | 0.90 | MAOA (0.44) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2810019 | 0.88 | MAOA (0.43) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL16808384 | 0.84 | MAOA (0.40) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1279762 | 0.81 | MAOA (0.55) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL30800165 | 0.81 | MAOA (0.55) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL7901300 | 0.80 | ENPP2 (0.46) | CYP4F2CYP4A11ALDH1A1TSHRCHRM2 | |
| SCHEMBL5915583 | 0.80 | L3MBTL1 (0.45) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL12345479 | 0.80 | CHRM2 (0.40) | CYP4F2CYP4A11ALDH1A1TSHRCHRM2 | |
| SCHEMBL910179 | 0.79 | MAOA (0.46) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561993-A1 | INHIBITORS OF PLASMA KALLIKREIN | Rezolute, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024025907-A1 | INHIBITORS OF PLASMA KALLIKREIN | REZOLUTE, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-7754727-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| EP-1689712-B1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | SEDRANI RICHARD | 2007-04-05 | — | — | US | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| EP-1689712-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MAOA 2103/4885MAOB 1521/4885NPC1 2069/4885 |
| US-20080269255-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | MAOA 229/4885MAOB 257/4885NPC1 400/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | MAOA 1359/4885MAOB 954/4885NPC1 1488/4885 |
| US-20100240679-A1 | 4-Phenylpiperidine Derivatives as Renin Inhibitors | REN, AGTR1, ACE | MAOA 231/4885MAOB 268/4885NPC1 431/4885 |
| US-20070078164-A1 | 4-Phenylpiperidine derivatives as renin inhibitors | REN, AGTR1, ACE | MAOA 231/4885MAOB 268/4885NPC1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.